Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
*Purpose: Previous studies have recommended a 2-5-year waiting time prior to kidney transplantation (KT) in patients with end-stage renal disease (ESRD) and symptomatic renal cell carcinoma (RCC) and no delay for incidental early-stage RCC. Data on Asian kidney transplant recipients are unavailable.
*Methods: This is a Korean single-center retrospective study on 35 KT recipients with ESRD and RCC (Figure 1). Patients were classified into two groups: early KT (KT performed within 1 year after nephrectomy for RCC, including KT with simultaneous nephrectomy) and delayed KT (KT performed > 1 year after nephrectomy for RCC). Patient survival, graft survival, and cancer recurrence were compared between both groups.
*Results: There were no statistically significant differences in patient survival (P = 0.388, Figure 2A), graft survival (P = 0.317, Figure 2B), or graft rejection rate (P = 0.207) between the early and delayed KT groups. Additionally, there were no differences in pathological characteristics and RCC stage other than cancer histology: acquired cystic disease-associated RCC (47.4%) was the most common RCC type in the early KT group, whereas clear cell type (66.7%) was the most common RCC type in the delayed KT group. No RCC recurrence was observed.
*Conclusions: Patients with early-stage and asymptomatic RCC do not require a mandatory observational period prior to KT after curative nephrectomy.
To cite this abstract in AMA style:Baek C, Kim H, Park S. Clinical Features and Transplant Outcomes in Kidney Transplant Recipients with Renal Cell Carcinoma [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-features-and-transplant-outcomes-in-kidney-transplant-recipients-with-renal-cell-carcinoma/. Accessed March 4, 2021.
« Back to 2020 American Transplant Congress